Atea Pharmaceuticals, Inc. cash flow to debt ratio of -15.66K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Atea Pharmaceuticals, Inc.'s free cash flow has increased -2.56% from $-135.50M last year to $-132.03M, signaling increasing performance

Atea Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Atea Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Atea Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Atea Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Atea Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Atea Pharmaceuticals, Inc.'s short-term assets of $310.99M exceed its short-term liabilities of $39.78M

Atea Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Atea Pharmaceuticals, Inc.'s return on equity of -57.01%, is lower than 15.00%, indicating bad performance

Atea Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Atea Pharmaceuticals, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Atea Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Atea Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Atea Pharmaceuticals, Inc.'s yearly earnings has increased -5.96% since last year from $-168.38M to $-158.35M, signaling increasing performance

Atea Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -78.11% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Atea Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Atea Pharmaceuticals, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Atea Pharmaceuticals, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Atea Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Atea Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Atea Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Atea Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Atea Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Atea Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Atea Pharmaceuticals, Inc. has a price-to-book ratio of 1.52x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Atea Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue